Challenge for the galenic: Development of new taxane formulations;Herausforderung an die galenik: Entwicklung neuer taxan-formulierungen

Pharmazie in Unserer Zeit

Volumn 34, Issue 2, 2005, Pages 115-121

  Haas, Heinrich ^a  

^a MediGene AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLODEXTRIN; DOCETAXEL; ONCOGEL; PACLITAXEL; PAXORAL; REGEL; TAXANE DERIVATIVE; XYTOTAX; ANTINEOPLASTIC AGENT; DRUG CARRIER; LIPOSOME; TAXOID;

ARTICLE; CANCER; DRUG FORMULATION; DRUG SOLUBILITY; EMULSION; LIPOPHILICITY; ANIMAL; CHEMISTRY; COLLOID; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; DRUG CARRIERS; HUMANS; LIPOSOMES; TAXOIDS;

EID: 17544364014     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200400111     Document Type: Article

References (23)

1. Huizing, M.T., Misser, V.H., Pieters, R.C., ten Bokkel, Huinink W.W., Veenhof, C.H., Vermerken, J.B., Pinedo, H.M., Beijnen, J.H.: Taxanes: a new class of antitumor agents. Cancer Invest. 13 (1995), 381-404
2. van Zuylen, L., Verweij, J., Sparreboom, A.: Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19 (2001), 125-141.
3. Nuijen, B., Bouman M., Schellens, H.M., Beijnen, J.H.: Progress in the development of alternative pharmaceutical formulations of taxanes. Invest. New Drugs 19 (2001), 143-153.
4. Singla, A.K., Garg, A., Deepika, A.: Paclitaxel and its formulations. Int. J. Pharm. 235 (2002), 179-192.
5. Malingre, M.M., Beijnen, J.H., Schellens, J.H.: Oral delivery of taxanes. Invest New Drugs 19 (2001) 155-162.
6. Gautam, A., Koshkina, N.: Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr. Cancer Drug Targets 3 (2003), 287-296.
7. Harper, E., Dang, W., Lapidus, R.G., Garver, R.I. Jr.: Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin. Cancer Res. 5 (1999), 4242-4248.
8. Ehrlich, A., Booher, S., Becerra, Y., Borris, D.L., Figg, W.D., Turner, M.L, Blauveit, A.: Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J. Am. Acad. Dermatol. 50 (2004), 533-540.
9. Bissery, M.C: Preclinical evaluation of new taxoids. Curr. Pharm. Des. 7 (2001), 1251-1257.
10. Wolff, A.C., Donehower, R.C., Carducci, M.K., Carducci, M.A., Brahmer, J.R., Zabelina, Y., Bradley, M.O., Anthony, F.H., Swindell, C.S., Witman, P.A., Webb, N.L., Baker, S.D.: Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin. Cancer Res. 9 (2003), 3589-3597.
11. Lundberg, B.B., Risovic, V., Ramaswamy, M. Wasan, K.M.: A lipophilic paclitaxel derivate incorporated in a lipid emulsion for parenteral administration J. Control. Release 86 (2003), 93-100.
12. Dosio, F., Brusa, P., Crosasso, P., Arpicco, S., Cartel, L: Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Control. Released (1997), 293-304.
13. Thurston, G., McLean, J. W., Rizen, M., Baluk, P., Haskell, A., Murphy, T. J., Hanahan, D., McDonald, D. M., Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101 (1998), 1401-1413.
14. Gao, Z., Lukyanov, A.N., Chakilam, A.R., Torchilin, V.P.: PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J. Drug Target. 11 (2003), 87-92.
15. Perkins, W.R., Ahmad, I., Li, X., Hirsh, D.J., Masters, G.R., Feco, C.J., Lee, J.K., Ali, S., Nguyen, J., Schupsky, J., Herbert, C., Janoff, A.S., Mayheff, E.: Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int. J. Pharm. 200 (2000), 27-39.
16. Immordino, M.L., Brusa, P, Arpicco, S, Stella, B, Dosio, F, Cattel, L.: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release 91 (2003), 417-429.
17. Ceruti, M., Crosasso, P., Brusa, P., Arpicco, S., Dosio, F., Cattel, L., Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J. Control. Release 63 (2000), 141-153.
18. Kunstfeld, R., Wickenhauser, G., Michaelis, U., Teifel, M., Umek, W., Naujoks, K., Wolff, K., Petzelbauer, P.: Paxlitaxel Encapsulated in Cationic Liposomes Diminishes Tumor Angiogenesis and Melanoma Growth in a "Humanized" SCID Mouse Model. J. Invest. Dermatol. 120 (2003), 476-482.
19. Soepenberg, O., Sparreboom, A., de Jonge, M.J., Planting, A.S., de Heus, G., Loos, W.J., Hartman, C.M., Bowden, C., Verweij, J.: Realtime pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. Eur. J. Cancer 40 (2004), 681-688.
20. Wenk, M.R. Fahr, A., Reszka, R., Seelig J.: Paclitaxel Partitioning into Lipid Bilayers. J. Pharm. Sci. 85 (1995), 228-231.
21. Ceruti, M., Crosasso, P., Brusa, P., Arpicco, S., Dosio, F., Cattel, L.: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J. Control. Released (2000), 141-153.
22. Battaglia, A., Bertucci, C., Bombardelli, E., Cimitan, S., Guerrini, A., Morazzoni, P., Riva, A.: Synthesis and HSA binding characterisation of the water soluble 7-succinylpaclitaxel. Eur. J. Med. Chem. 38 (2003), 383-389
23. OOya, T., Lee, J., Park, K.: Hydrotropic Dendrimers of Generations 4 and 5: Synthesis, Characterization, and Hydrotropic Solubilization of Paclitaxel. Bioconjugate Chem. 15 (2004) 1221-1229